Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290055 | 0.76 | GAA (0.47) | — | |
| SCHEMBL13035367 | 0.75 | HSD17B10 (0.31) | — | |
| SCHEMBL15551259 | 0.75 | ACHE (0.63) | ACHEEPHX2 | |
| SCHEMBL20048945 | 0.75 | MEN1 (0.47) | — | |
| SCHEMBL15868092 | 0.74 | ADRA1A (0.47) | — | |
| SCHEMBL16134192 | 0.74 | FAAH (0.47) | EPHX2 | |
| SCHEMBL27353599 | 0.74 | ACHE (0.61) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL20663435 | 0.73 | EPHX2 (0.67) | ACHEEPHX2 | |
| SCHEMBL5700191 | 0.73 | ACHE (0.65) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL7769333 | 0.73 | ACHE (0.55) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061872-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200207822-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | PROTAGONIST THERAPEUTICS, INC. | 2020-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061872-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, HDGF, FTH1 | ACHE 4885/4885CHRNB2 4876/4885CHRNB4 4881/4885 |
| US-20200207822-A1 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES | IL23R, IL1RN, VIP | ACHE 4856/4885CHRNB2 4210/4885CHRNB4 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.